Geneplus-Beijing Co. Ltd.   Report issue

For profit Phase 1 Phase 3
Founded: Beijing China (2010)

Organization Overview

First Clinical Trial
2017
NCT03038217
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Geneplus-Beijing Co. Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

capecitabine (xeloda) (2 trials)

oxaliplatin (eloxatin) (2 trials)

Drugs in Phase 1 Trials (2)

lenvatinib (lenvima) (1 trial)

tislelizumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Rectal Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4